Skip to main content

The Abuse Potential of Prescription Opioids in Humans—Closing in on the First Century of Research

  • Chapter
  • First Online:

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 34))

Abstract

While opioids are very effective analgesics for treating acute pain, humans have struggled with opiate addiction for millenia. An opium abuse epidemic in the early 1900’s led the US government to develop a systematic research infrastructure and scientific plan to produce new compounds with analgesic properties but without abuse liability. This review describes the techniques that were developed for testing in the human laboratory, including empirically derived outcome measures and required elements for human abuse potential assessment. The evaluation and characterization of semi-synthetic and synthetic opioids, including full mu opioid agonists, partial agonists and mixed agonist-antagonists, are described across several decades of research. Finally, the prescription opioid epidemic beginning in the 1990’s in the US led to a resurgence in abuse potential evaluations, and the application of these methods to the study of novel abuse-deterrent formulations is discussed.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Abreu ME, Bigelow GE, Fleisher L, Walsh SL (2001) Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology 154:76–84

    Article  CAS  PubMed  Google Scholar 

  • Alves EA, Soares JX, Afonso CM, Grund JP, Agonia AS, Cravo SM, Netto AD, Carvalho F, Dinis-Oliveira RJ (2015) The harmful chemistry behind “krokodil”: street-like synthesis and product analysis. Forensic Sci Int 257:76–82

    Article  CAS  PubMed  Google Scholar 

  • Ardakani YH, Rouini MR (2007) Pharmacokinetics of tramadol and its three main metabolites in healthy male and female volunteers. Biopharm Drug Dispos 28:527–534

    Article  CAS  PubMed  Google Scholar 

  • Babalonis S, Lofwall MR, Nuzzo PA, Siegel AJ, Walsh SL (2013) Abuse liability and reinforcing efficacy of oral tramadol in humans. Drug Alcohol Depend 129:116–124

    Article  CAS  PubMed  Google Scholar 

  • Babalonis S, Lofwall MR, Nuzzo PA, Walsh SL (2014) Pharmacodynamic effects or oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans. Addict Biol e-pub ahead of print

    Google Scholar 

  • Balster RL, Bigelow GE (2003) Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70:S13–S40

    Article  PubMed  Google Scholar 

  • Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM (2000) Comparative abuse liability of intravenously administered remifentanil and fentanyl. J Clin Psychopharmacol 20:597–606

    Article  CAS  PubMed  Google Scholar 

  • Bickel WK, Preston KL, Bigelow GE, Liebson IA (1986) Three-way drug discrimination in post-addict volunteers: hydromorphone, pentazocine, and saline. NIDA Res Monogr 67:177–183

    CAS  PubMed  Google Scholar 

  • Blanch B, Pearson SA, Haber PS (2014) An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol 78:1159–1166

    Article  PubMed  PubMed Central  Google Scholar 

  • Campbell ND, Olsen JP, Walden L (2008) The narcotic farm the rise and fall of America’s first prison for drug addicts. Abrams Books, New York

    Google Scholar 

  • Carter LP, Griffiths RR (2009) Principles of laboratory assessment of drug abuse liability and implictations for clinical development. Drug Alcohol Depend (in press)

    Google Scholar 

  • Casati A, Sedefov R, Pfeiffer-Gerschel T (2012) Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 18:228–245

    Article  PubMed  Google Scholar 

  • CDC (2016) CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Morb Mortal Wkly Rep 65:1–49

    Google Scholar 

  • Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Reyo RA (2015) The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 162:276–286

    Google Scholar 

  • Clark NC, Lintzeris N, Muhleisen PJ (2002) Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Med J Aust 176:166–167

    PubMed  Google Scholar 

  • Colucci SV, Perrino PJ, Shram M, Bartlett C, Wang Y, Harris SC (2014) Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users. Clin Drug Investig 34:421–429

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Comer SD, Collins ED, MacArthur RB, Fischman MW (1999) Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology 143:327–338

    Article  CAS  PubMed  Google Scholar 

  • Comer SD, Collins ED, Fischman MW (2002) Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther 301:266–276

    Article  CAS  PubMed  Google Scholar 

  • Comer SD, Sullivan MA, Walker EA (2005) Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 315:1320–1330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL (2008a) The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 96:1–15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Comer SD, Sullivan MA, Whittington RA, Vosberg SK, Kowalczyk WJ (2008b) Abuse liabliity of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33:1179–1191

    Article  CAS  PubMed  Google Scholar 

  • Comer SD, Sullivan MA, Vosburg SK, Kowalczyk WJ, Houser J (2010) Abuse liability of oxycodone as a function of pain and drug use history. Drug Alcohol Depend 109:130–138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O’Brien C, O’Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL (2012) Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain 153:2315–2324

    Article  PubMed  PubMed Central  Google Scholar 

  • Comer SD, Metz VE, Cooper ZD, Kowalczyk WJ, Jones JD, Sullivan MA, Manubay JM, Vosburg SK, Smith ME, Peyser D, Saccone PA (2013) Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. Behav Pharmacol 24:504–516

    Article  PubMed  PubMed Central  Google Scholar 

  • Commiskey S, Fan L-W, Ho IK, Rockhold RW (2005) Butorphanol: effects of a prototypical agonist-antagonist analgesic on k-opioid receptors. J Pharmacol Sci 98:109–116

    Article  CAS  PubMed  Google Scholar 

  • Compton WM, Volkow ND (2006) Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 83(Suppl 1):S4–S7

    Article  CAS  PubMed  Google Scholar 

  • Cowan A, Lewis JW, Macfarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537–545

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • CSAT (2004) Clinical guidelines for buprenorphine in the treatment of opioid addiction. Substance abuse and mental health services administration

    Google Scholar 

  • de Quincy T (1823) Confessions of an English Opium-eater. Taylor and Hessey, London

    Google Scholar 

  • Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL (2005) Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100:1496–1509

    Article  PubMed  Google Scholar 

  • Duke AN, Correia CJ, Walsh SL, Bigelow GE, Strain EC (2010) Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. Psychopharmacology 211:303–312

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Duke AN, Bigelow GE, Lanier RK, Strain EC (2011) Discriminative stimulus effects of tramadol in humans. J Pharmacol Exp Ther 338:255–262

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Eddy NB (1956) Synthetic substances with morphine-like effect. Bull World Health Organ 114:353–402

    Google Scholar 

  • Eddy NB (1973) The national research council involvement in the opiate problem. National Academy of Sciences, Washington, DC

    Google Scholar 

  • Eddy NB, Lee LE Jr (1959) The analgesic equivalence to morphine and relative side action liability of oxymorphone (14-hydroxydihydro morphinone). J Pharmacol Exp Ther 125:116–121

    CAS  PubMed  Google Scholar 

  • Eddy NB, Lee LE Jr, Harris C (1959) Physical dependence and tolerance in relation to various analgesics in patients suffering from chronic pains; comparison between morphine, oxymorphone and anileridine. Bull World Health Organ 20:1245–1256

    CAS  PubMed  PubMed Central  Google Scholar 

  • Eddy NB, Friebel H, Hahn KJ, Halbach H (1968) Codeine and its alternates for pain and cough relief. I. Codeine, exclusive of its antitussive action. Bull World Health Organ 38:673–741

    CAS  PubMed  PubMed Central  Google Scholar 

  • Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH (2006) The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 102:146–150

    Article  CAS  PubMed  Google Scholar 

  • Epstein DH, Preston KL, Jasinski DR (2006) Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychiatry 73:90–99

    Article  Google Scholar 

  • FDA (2009) Format and content of proposed risk evaluation and mitigation strategies (REMS), REMS assessments, and proposed REMS modifications. In: U.S. Department of Health and Human Services, F.A.D.A., Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (Ed.). U.S. Department of Health and Human Services, Rockville, MD

    Google Scholar 

  • FDA (2010) Guidance for industry: assessment of abuse potential of drugs. In: U.S. Department of Health and Human Services, F.A.D.A., Center for Drug Evaluation and Research (CDER) (Ed.), Silver Spring, MD

    Google Scholar 

  • FDA (2015) Abuse-deterrent opioids—evaluation and labeling guidance for industry. In: U.S. Department of Health and Human Services, F.A.D.A., Center for Drug Evaluation and Research (CDER) (ed) U.S. Department of Health and Human Services

    Google Scholar 

  • Fischer B, Rehm J, Kirst M, Casas M, Hall W, Krausz M, Metrebian N, Reggers J, Uchtenhagen A, van den Brink W, van Ree JM (2002) Heroin-assisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health 12:228–234

    Article  PubMed  Google Scholar 

  • Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter MT, Strang J, van den Brink W (2007) Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health 84:552–562

    Article  PubMed  PubMed Central  Google Scholar 

  • Fischer B, Jones W, Murphy Y, Ialomiteanu A, Rehm J (2015) Recent developments in prescription opioid-related dispensing and harm indicators in Ontario, Canada. Pain Physician 18:E659–E662

    PubMed  Google Scholar 

  • Fraser HF, Rosenberg DE (1964) Studies on the human addiction liability of 2′-hydroxy-5, 9-dimethyl-2-(3,3-dimethylallyl)-6, 7-benzmorphan (WIN 20, 228): a weak narcotic antagonist. J Pharmacol Exp Ther 143:149–156

    CAS  PubMed  Google Scholar 

  • Fraser HF, Van Horn GG, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) “Attitude of opiate addicts toward opiate-like drugs, (B) A short-term direct” addiction test. J Pharmacol Exp Ther 133:371–378

    CAS  PubMed  Google Scholar 

  • Fraser HF, Nash TL, Vanhorn GD, Isbell H (1976) Use of miotic effect in evaluating analgesic drugs in man. 1954 (proceedings). NIDA Res Monogr, p 60

    Google Scholar 

  • Fraser HF, Kay DC, Yeh SY, Gorodetzky CW, Dewey WL (1978) Possible effects of normetabolites on the subjective and reinforcing characteristics of opioids in animals and man. Drug Alcohol Depend 3:301–318

    Article  CAS  PubMed  Google Scholar 

  • Greenwald MK (2008) Behavioral economic analysis of drug preference using multiple choice procedure data. Drug Alcohol Depend 93:103–110

    Article  PubMed  Google Scholar 

  • Greenwald MK, Stitzer ML (1998) Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine. Drug Alcohol Depend 53:17–30

    Article  CAS  PubMed  Google Scholar 

  • Greenwald MK, June HL, Stitzer ML, Marco AP (1996) Comparative clinical pharmacology of short-acting mu opioids in drug abusers. J Pharmacol Exp Ther 277:1228–1236

    CAS  PubMed  Google Scholar 

  • Haertzen CA (1974) An overview of addiction research center inventory scales (ARCI): an appendix and manual of scales. In: Abuse, N.I.O.D. (ed) Department of Health, Education and Welfare, Rockville, MD

    Google Scholar 

  • Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM (2014) Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol 54:468–477

    Article  PubMed  CAS  Google Scholar 

  • Heishman SJ, Schuh KJ, Schuster CR, Henningfield JE, Goldberg SR (2000) Reinforcing and subjective effects of morphine in human opioid abusers: effect of dose and alternative reinforcer. Psychopharmacology 148:272–280

    Article  CAS  PubMed  Google Scholar 

  • Hill JL, Zacny JP (2000) Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology 152:31–39

    Article  CAS  PubMed  Google Scholar 

  • Horan PJ, Ho IK (1989) Comparative pharmacological and biochemical studies between butorphanol and morphine. Pharmacol Biochem Behav 34:847–854

    Article  CAS  PubMed  Google Scholar 

  • Isbell H, Vogel VH (1949) The addiction liability of methadon (amidone, dolophine, 10820) and its use in the treatment of the morphine abstinence syndrome. Am J Psychiatry 105:909–914

    Article  CAS  PubMed  Google Scholar 

  • Isbell H, Wikler A et al (1947) Tolerance and addiction liability of 6-dimethylamino-4-4-diphenylheptanone-3 (methadon). J Am Med Assoc 135:888–894

    Article  CAS  PubMed  Google Scholar 

  • Jaffe JH, Martin WR (1991) Opioid analgesics and antagonists. In: Gilman AG, Rall RW, Nies AS, Taylor P (eds) Goodman and gilman’s the pharmacological basis of therapeutics. Maxwell Macmillan International Editions, Elmsford, New York, pp 485–521

    Google Scholar 

  • Jasinski DR (1977) Assessment of the abuse potentiality of morphinelike drugs (methods used in man). In: Martin WR (ed) Drug addiction I. Springer, Berlin, pp 197–258

    Chapter  Google Scholar 

  • Jasinski DR, Mansky PA (1972) Evaluation of nalbuphine for abuse potential. Clin Pharmacol Ther 13:78–90

    Article  CAS  PubMed  Google Scholar 

  • Jasinski DR, Nutt JG (1972) Progress report on the assessment program of the NIMH addiction research center. In: U.S. Department of Health, E., and Welfare, Public Health Service, Health Services and Mental Health Administration, National Institute of Mental Health, (ed) National, Lexington, Kentucky, pp 442–477

    Google Scholar 

  • Jasinski DR, Preston KL (1986) Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend 17:301–310

    Article  CAS  PubMed  Google Scholar 

  • Jasinski DR, Martin WR, Hoeldtke RD (1970) Effects of short- and long-term administration of pentazocine in man. Clin Pharmacol Ther 11:385–403

    Article  CAS  PubMed  Google Scholar 

  • Jasinski DR, Griffith JD, Pevnick JS, Clark SC (1975) Progress report on studies for he clinical pharmacology section of the addiction research center. National Academy of Sciences, Washington, DC, pp 121–161

    Google Scholar 

  • Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35:501–516

    Article  CAS  PubMed  Google Scholar 

  • Jasinski DR, Fudala PJ, Johnson RE (1989) Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther 45:513–519

    Article  CAS  PubMed  Google Scholar 

  • Jasinski DR, Preston KL, Sullivan JT, Testa MP (1993) Abuse potential of oral tramadol. In: 55th Annual meeting of the college on problems of drug dependence, p 103

    Google Scholar 

  • Jones JD, Madera G, Comer SD (2014) The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users. Pharmacol Biochem Behav 122:299–306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD (2015) Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addict Biol 20:784–798

    Article  CAS  PubMed  Google Scholar 

  • Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM (1997) Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 281:103–108

    CAS  PubMed  Google Scholar 

  • Kathiramalainathan K, Kaplan HL, Romach MK, Busto UE, Li NY, Sawe J, Tyndale RF, Sellers EM (2000) Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. J Clin Psychopharmacol 20:435–444

    Article  CAS  PubMed  Google Scholar 

  • Kim I, Barnes AJ, Oyler JM, Schepers R, Joseph RE Jr, Cone EJ, Lafko D, Moolchan ET, Huestis MA (2002) Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. Clin Chem 48:1486–1496

    CAS  PubMed  Google Scholar 

  • Klous MG, Van den Brink W, Van Ree JM, Beijnen JH (2005) Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug Alcohol Depend 80:283–295

    Article  CAS  PubMed  Google Scholar 

  • Lamas X, Farre M, Cami J (1994) Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers. J Pharmacol Exp Ther 268:1485–1492

    CAS  PubMed  Google Scholar 

  • Lamb RJ, Preston KL, Schindler CW, Meisch RA, Davis F, Katz JL, Henningfield JE, Goldberg SR (1991) The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 259:1165–1173

    CAS  PubMed  Google Scholar 

  • Lewis JW (1974) C-bridged derivatives of thebaine and oripavine. Adv Biochem Pharmacol 8:123–136

    Google Scholar 

  • Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J (2007) Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend 91:187–194

    Article  CAS  PubMed  Google Scholar 

  • Lofwall MR, Walsh SL (2014) A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med 8:315–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lofwall MR, Nuzzo PA, Walsh SL (2012) Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusers. Drug Alcohol Depend 123:229–238

    Article  CAS  PubMed  Google Scholar 

  • Marsch LA, Bickel WK, Badger GJ, Rathmell JP, Swedberg MD, Jonzon B, Norsten-Hoog C (2001) Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 299:1056–1065

    CAS  PubMed  Google Scholar 

  • Martin WR (1983) Pharmacology of opioids. Pharmacol Rev 35:283–323

    CAS  PubMed  Google Scholar 

  • McAvoy BR, Dobbin MD, Tobin CL (2011) Over-the-counter codeine analgesic misuse and harm: characteristics of cases in Australia and New Zealand. NZ Med J 124:29–33

    Google Scholar 

  • McNair DM, Lorr M, Droppleman LF (1971) EITS manual for the profile of mood states. Educational and Industrial Testing Service, San Diego

    Google Scholar 

  • Mendelson J, Jones RT, Welm S, Baggot M, Fernandez I, Melby AK, Nath RP (1999) Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology 141:37–46

    Article  CAS  PubMed  Google Scholar 

  • Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL (2011) The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction 106:1460–1473

    Article  PubMed  PubMed Central  Google Scholar 

  • Middleton LS, Lofwall MR, Nuzzo PA, Siegel AJ, Walsh SL (2012) Intranasal oxycodone self-administration in non-dependent opioid abusers. Exp Clin Psychopharmacol 20:310–317

    Article  CAS  PubMed  Google Scholar 

  • Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM (1993) CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 54:463–472

    Article  CAS  PubMed  Google Scholar 

  • Peters RJ Jr, Williams M, Ross MW, Atkinson J, Yacoubian GS Jr (2007) Codeine cough syrup use among African-American crack cocaine users. J Psychoactive Drugs 39:97–102

    Article  PubMed  Google Scholar 

  • Pickworth WB, Johnson RE, Holicky BA, Cone EJ (1993) Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 53:570–576

    Article  CAS  PubMed  Google Scholar 

  • Pircio AW, Gylys JA, Cavanagh RL, Buyniski JP, Bierwagen ME (1976) The pharmacology of butorphanol, a 3, 14-dihydroxymorphinan narcotic antagonist analgesic. Arch Int Pharmacodyn Ther 220:231–257

    CAS  PubMed  Google Scholar 

  • Preston KL, Bigelow GE (1993) Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264:813–823

    CAS  PubMed  Google Scholar 

  • Preston KL, Bigelow GE (1994) Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure. J Pharmacol Exp Ther 271:48–60

    CAS  PubMed  Google Scholar 

  • Preston KL, Walsh SL (1998) Evaluating abuse liability: methods and predictive value. In: Karch SB (ed) drug abuse handbook. CRC Press, Boca Raton, pp 276–306

    Google Scholar 

  • Preston KL, Bigelow GE, Liebson IA (1987) Comparative evaluation of morphine, pentacozine and ciramadol in postaddicts. J Pharmacol Exp Ther 240:900–910

    CAS  PubMed  Google Scholar 

  • Preston KL, Bigelow GE, Liebson IA (1988) Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharmacol Exp Ther 246:441–448

    CAS  PubMed  Google Scholar 

  • Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989a) Drug discrimination in human postaddicts: agonist-antagonist opioids. J Pharmacol Exp Ther 250:184–196

    CAS  PubMed  Google Scholar 

  • Preston KL, Bigelow GE, Liebson IA (1989b) Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther 248:929–937

    CAS  PubMed  Google Scholar 

  • Preston KL, Bigelow GE, Liebson IA (1990) Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacol Biochem Behav 37:511–522

    Article  CAS  PubMed  Google Scholar 

  • Preston KL, Jasinski DR, Testa M (1991) Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 27:7–17

    Article  CAS  PubMed  Google Scholar 

  • Preston KL, Liebson IA, Bigelow GE (1992) Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination. J Pharmacol Exp Ther 261

    Google Scholar 

  • PurduePharma (2015) OXYCONTIN—oxycodone hydrochloride tablet, film coated, extended release Package Insert. In: LP, P.P. (ed)

    Google Scholar 

  • Romach MK, Schoedel KA, Sellers EM (2014) Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology 87:81–90

    Article  CAS  PubMed  Google Scholar 

  • Rosado J, Walsh SL, Bigelow GE, Strain EC (2007) Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug Alcohol Depend 90:261–269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM (2011) Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. J Opioid Manag 7:179–192

    Article  PubMed  Google Scholar 

  • Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E (2012) Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta) tablets in nondependent recreational opioid users. J Opioid Manag 8:315–327

    Article  PubMed  Google Scholar 

  • Schuh KJ, Walsh SL, Bigelow GE, Preston KL, Stitzer ML (1996) Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther 278:836–846

    CAS  PubMed  Google Scholar 

  • Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, Webster LR (2014) Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155:1829–1835

    Article  CAS  PubMed  Google Scholar 

  • Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL (2010) Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology 212:193–203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stoops WW, Lofwall MR, Nuzzo PA, Craig LB, Siegel AJ, Walsh SL (2012) Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology 223:427–438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stoops WW, Glaser PE, Rush CR (2013) Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users. Psychopharmacology 228:255–262

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Strain EC, Preston KL, Liebson IA, Bigelow GE (1992) Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 261:985–993

    CAS  PubMed  Google Scholar 

  • Strain EC, Preston KL, Liebson IA, Bigelow GE (1993) Precipitated withdrawal by pentazocine in methadone-maintained volunteers. J Pharmacol Exp Ther 267:624–634

    CAS  PubMed  Google Scholar 

  • Strain EC, Preston KL, Liebson IA, Bigelow GE (1995) Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 272:628–638

    CAS  PubMed  Google Scholar 

  • Strain EC, Walsh SL, Preston KL, Liebson IA, Bigelow GE (1997) The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology 129:329–338

    Article  CAS  PubMed  Google Scholar 

  • Strain EC, Stoller K, Walsh SL, Bigelow GE (2000) Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology 148:374–383

    Article  CAS  PubMed  Google Scholar 

  • Sullivan MA, Vosburg SK, Comer SD (2006) Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 189:37–46

    Article  CAS  PubMed  Google Scholar 

  • Toll L, Bruchas MR, Calo G, Cox BM, Zaveri NT (2016) Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev 68:419–457

    Article  PubMed  PubMed Central  Google Scholar 

  • Tompkins DA, Smith MT, Bigelow GE, Moaddel R, Venkata SL, Strain EC (2014) The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males. Clin J Pain 30:36–45

    Article  PubMed  Google Scholar 

  • Umbricht A, Huestis MA, Cone EJ, Preston KL (2004) Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol 24:479–487

    Article  CAS  PubMed  Google Scholar 

  • Van Zee A (2009) The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health 99:221–227

    Article  PubMed  PubMed Central  Google Scholar 

  • Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, Kropp TJ, Verbois SL (2011) Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 59:385–390

    Article  CAS  PubMed  Google Scholar 

  • Walker DJ, Zacny JP (1998) Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. Psychopharmacology 140:191–201

    Article  CAS  PubMed  Google Scholar 

  • Walker DJ, Zacny JP (1999) Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J Pharmacol Exp Ther 289:1454–1464

    CAS  PubMed  Google Scholar 

  • Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569–580

    Article  CAS  PubMed  Google Scholar 

  • Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML (1995a) Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 119:268–276

    Article  CAS  PubMed  Google Scholar 

  • Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995b) Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274:361–372

    CAS  PubMed  Google Scholar 

  • Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157:151–162

    Article  CAS  PubMed  Google Scholar 

  • Walsh SL, Chausmer AE, Strain EC, Bigelow GE (2008a) Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology 196:143–155

    Article  CAS  PubMed  Google Scholar 

  • Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr (2008b) The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 98:191–202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Walsh SL, Heilig M, Nuzzo PA, Henderson P, Lofwall MR (2012) Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol e-pub ahead of print

    Google Scholar 

  • Webster LR, Bath B, Medve RA, Marmon T, Stoddard GJ (2012) Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Pain Med 13:790–801

    Article  PubMed  Google Scholar 

  • Weinhold LL, Preston KL, Farre M, Liebson IA, Bigelow GE (1992) Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend 30:263–274

    Article  CAS  PubMed  Google Scholar 

  • White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, Nichols DE, Malanga CJ, Roth BL (2015) The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther 352:98–109

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wikler A, Fraser HF, Isbell H (1953) N-Allylnormorphine: effects of single doses and precipitation of acute abstinence syndromes during addiction to morphine; methadone or heroin in man (post addicts). J Pharmacol Exp Ther 109:8–20

    CAS  PubMed  Google Scholar 

  • Zacny JP, Lichtor SA (2008) Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology 196:105–116

    Article  CAS  PubMed  Google Scholar 

  • Zacny JP, Gutierrez S (2009) Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug Alcohol Depend 101:107–114

    Article  CAS  PubMed  Google Scholar 

  • Zacny JP, Lichtor JL, Zaragoza JG, de Wit H (1992) Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology 107:319–326

    Article  CAS  PubMed  Google Scholar 

  • Zacny JP, Lichtor JL, Binstock W, Coalson DW, Cutter T, Flemming DC, Glosten B (1993) Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers. Psychopharmacology 111:306–314

    Article  CAS  PubMed  Google Scholar 

  • Zacny JP, Lichtor JL, Thapar P, Coalson DW, Flemming D, Thompson WK (1994) Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers. J Pharmacol Exp Ther 270:579–588

    CAS  PubMed  Google Scholar 

  • Zacny JP, McKay MA, Toledano AY, Marks S, Young CJ, Klock PA, Apfelbaum JL (1996) The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers. Drug Alcohol Depend 42:133–142

    Article  CAS  PubMed  Google Scholar 

  • Zacny JP, Gutierrez S, Bolbolan SA (2005) Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users. Drug Alcohol Depend 78:243–252

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sharon L. Walsh .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Walsh, S.L., Babalonis, S. (2016). The Abuse Potential of Prescription Opioids in Humans—Closing in on the First Century of Research. In: Nielsen, S., Bruno, R., Schenk, S. (eds) Non-medical and illicit use of psychoactive drugs. Current Topics in Behavioral Neurosciences, vol 34. Springer, Cham. https://doi.org/10.1007/7854_2016_448

Download citation

Publish with us

Policies and ethics